Phase 2bData readout

Obefazimod

Crohn’s Disease

ABVXAbivax

Expected catalystAugust 15, 2027Company guidance: Aug 15, 2027

Catalyst overview

Event details

Drug or asset: Obefazimod
Development stage: Phase 2b
Event type: Data readout
Indication: Crohn’s Disease

Research summary

What is being tracked?

This catalyst tracks a Phase 2b data readout for Obefazimod in Crohn’s Disease. The expected timing is based on the latest available company guidance and may change.

Development notes

05/22/26:- ENHANCE-CD Ph2b progressed. Induction topline data remain expected in Q4 2026. 06/01/26:- ENHANCE-CD Phase 2b induction topline results now expected Mid-2027.

Verification

Primary source

Confirm timing and program details against the company announcement or filing.

Open source